INTRODUCTION
============

Despite the advances in post-operative patient management and the availability of new immunosuppressive agents, overcoming and monitoring immune responses in kidney transplant recipients (KTRs) to ensure renal allograft survival remains a critical challenge for clinicians. Antibody-mediated rejection (AMR), rather than pure T cell mediated rejection (TCMR), is a major cause of late kidney transplant failure ([@B1]). Microcirculation inflammation (MI), defined as the sum of the glomerulitis (g) and peritubular capillaritis (ptc) scores, is a crucial histologic finding in AMR ([@B2]) and is associated with a poor prognosis for graft survival in KTRs ([@B3]).

Previous studies analyzing the immunohistological aspects of allograft rejection have demonstrated that human leukocyte antigen-antigen D related (HLA-DR) expressing cells and T lymphocytes ([@B4][@B5]), HLA-DR expressing monocytes ([@B6]), or macrophage infiltration ([@B7]) were increased in renal allografts with TCMR. Studies examining the immune status of peripheral blood have also reported increased circulating CD4^+^CD25^+^ and CD8^+^HLA-DR^+^ T lymphocytes ([@B8]), altered levels of circulating CD4^+^CD25^+^ regulatory T cells ([@B9]), and increased frequencies of circulating monocytes ([@B7]) in KTRs with TCMR. These immune reactions occurring in the renal allograft or peripheral blood ultimately result in tissue damage and renal allograft dysfunction.

Previous studies have demonstrated the clinical significance of MI, T lymphocytes, and monocytes in KTRs with acute rejection. However, there is limited information available on the association between MI in allograft biopsy and the activity of peripheral blood T lymphocytes and monocytes. The aim of the present study was to compare the histological grading of renal allografts, according to the Banff score, with the activity of circulating T lymphocyte subsets and HLA-DR-positive monocytes in KTRs.

MATERIALS AND METHODS
=====================

Study population and sample collection
--------------------------------------

Patients who underwent a major surgery within one month, patients with active infection, including HIV and viral hepatitis, and patients with autoimmune or hematologic disorders were excluded. We consecutively enrolled 82 KTRs with stable renal function at 2 weeks after kidney transplantation (KT) and 24 KTRs with acute renal allograft dysfunction who underwent indication biopsy. Circulating T lymphocyte subsets and HLA-DR positive monocytes were collected at 2 weeks after KT and at the time of indication biopsy, respectively. T lymphocytes and HLA-DR-positive monocytes were isolated from the peripheral blood samples. Data on the demographics, immunological status, and clinical characteristics at the time of KT and biopsy were collected. Donor-specific antibody (DSA) was determined by Luminex assays and expressed as mean fluorescence intensity (MFI).

Immunosuppressive treatment
---------------------------

Induction treatment with intravenously administered basiliximab was performed to all the patients. Patients received immunosuppressive treatment including corticosteroid, calcineurin inhibitor (CNI), and mycophenolate mofetil. Corticosteroid treatment included 500 mg intravenous methylprednisolone at the time of surgery and was tapered to 5 mg/day oral prednisolone after 6 months. The dosages of tacrolimus were adjusted to achieve the trough level of 8--12 ng/mL in the first 3 months and 5--8 ng/mL thereafter. The dosages of cyclosporine were adjusted to keep the trough level of 250--300 ng/mL in the first 3 months and 100--150 ng/mL thereafter. Mycophenolate mofetil was administered daily at a fixed dose of 1.0--2.0 g.

Histopathology
--------------

All biopsies were obtained before the treatment of the presumptive diagnosis. A total of 24 biopsy specimens were reviewed, according to the Banff 2013 classification. All assessments were made by a renal pathologist and a nephrologist, without any knowledge of the clinical and immunological status of the KTRs. Definitions of the terms used in the Banff 2013 classification system are as follows: g describes the percentage of glomeruli with increased infiltrating mononuclear cells, or the occlusion of the glomerular capillary by mononuclear cells and endothelial enlargement (range 0--3); ptc indicates the number of infiltrating neutrophils or mononuclear cells in \> 10% affected cortical peritubular capillaries (range 0--3); MI is the sum of g + ptc (range 0--6); interstitial inflammation (i) indicates the percentage of mononuclear inflammation in the nonfibrotic area, except the subcapsular cortex and perivascular area (range 0--3); tubulitis (t) indicates the number of mononuclear cells in the most severely inflamed tubule; for longitudinal sections, it is the count per 10 tubular epithelial nuclei (range 0--3); interstitial fibrosis (ci) indicates the percentage area of the cortex with fibrosis (range 0--3); tubular atrophy (ct) indicates the percentage area of the cortex with atrophic tubules (range 0--3); arterial fibrointimal thickening (cv) indicates the percentage of the lumen of most severely affected (range 0--3); and arteriolar hyaline thickening (ah) indicates the number of circumferential or non-circumferential focal hyaline deposits (range 0--3). Peritubular capillary deposition of C4d has been determined. The histologic grading of renal allograft was classified according to the sum of scores of g + ptc (MI), i + t, ci + ct, and cv + ah, based on Banff 2013 scheme as described above.

Flow cytometric analysis of T lymphocyte and monocyte subsets
-------------------------------------------------------------

The frequencies of peripheral blood CD4^+^, CD8^+^, CD25^+^, and HLA-DR^+^ T lymphocytes, and HLA-DR-positive monocytes were determined by flow cytometry. Whole blood was stained with fluorochrome-conjugated monoclonal antibodies for 20 minutes at room temperature, protected from light. The following antibodies (BD Biosciences, San Jose, Ca, USA) were used: anti-CD25-FITC, anti-CD8-PE-Cy5, anti-CD3-PE, anti-CD4-PE-Cy5, anti-CD14-PE, and anti-HLA/DR-FITC. The values were described as a percentage and as the MFI. RBCs were lysed (DN RBC Lysis Buffer; DiNonA Inc., Seoul, Korea) after incubation with fluorochrome-conjugated antibodies. Cells were washed once with and resuspended in phosphate buffered saline and were analyzed on a FACSCalibur Flow cytometer using the CellQuest software (both from BD Biosciences).

Immunohistochemistry
--------------------

The number of CD3^+^ T cells and CD68^+^ macrophages in glomerular and peritubular capillaries was assessed by immunoperoxidase staining. Tissue sections were incubated with rabbit polyclonal CD3 (Prediluted, clone 2GV6; Ventana, Tucsan, AZ, USA) or antihuman CD68 (1:50, clone PG-M1; DAKO, Carpenteria, CA, USA) primary antibody. Absolute numbers of intracapillary positive cells in 5 glomerular and peritubular capillaries were counted and mean number of positive cells per glomerular and peritubular capillary was presented.

Statistical analysis
--------------------

Continuous variables are expressed as mean ± standard deviation (SD) for normally distributed data and as the median with range when the values were not normally distributed. Differences in T lymphocyte subsets and monocyte percentages between the 2 groups based on histological scores and in mean numbers of positive cells for CD3 and CD68 according to the histological diagnosis were analyzed using the Mann-Whitney U test because of the non-normal distribution of all parameters. Correlations between the MI sum scores, the MFI of de novo DSA, and T lymphocyte subsets and HLA-DR-positive monocytes were measured using Spearman\'s correlation coefficient (*r*). The ability of CD4^+^HLA-DR^+^/CD4^+^ T cells to predict acute AMR was analyzed using the receiver operating characteristic (ROC) curves. Statistical analysis was performed using the SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). *P* values \< 0.05 were considered statistically significant.

Ethics statement
----------------

The Institutional Review Board of Kyungpook National University Hospital reviewed and approved the study protocol (No. KNUH-09-1015). All clinical investigations were conducted in accordance with the guidelines of the 2008 Declaration of Helsinki. All the patients provided written informed consent prior to enrollment.

RESULTS
=======

Demographics of KTRs who underwent indication biopsy and grouping
-----------------------------------------------------------------

The mean age of the KTRs at the time of biopsy was 46.1 years and 66.7% of the KTRs were male. Patients\' clinical characteristics are detailed in [Table 1](#T1){ref-type="table"}. Chronic glomerulonephritis was the most common cause of end-stage renal disease (58.3%). One patient (4.2%) and 2 patients (8.3%) underwent crossmatch-positive KT and ABO-incompatible KT, respectively. Three patients (12.5%) had pre-existing anti-human leukocyte antigen (HLA) antibody prior to KT. Among these 3 KTRs, 1 patient had DSA. The median time from KT to biopsy was 14 (range 0--94) months. All KTRs (n = 24) were divided into 2 groups according to the sum scores of g + ptc (MI), i + t, ci + ct, and cv + ah assessed on the renal allograft biopsy specimens (MI = 0 vs. MI ≥ 1; i + t = 0 vs. i + t ≥ 1, ci + ct = 0 vs. ci + ct ≥ 1, cv + ah = 0 vs. cv + ah ≥ 1).

###### Baseline characteristics of KTRs who underwent indication biopsy

![](jkms-32-908-i001)

  Variables                                Findings (n = 24)
  ---------------------------------------- -------------------
  Male sex                                 16 (66.7)
  Mean age, yr                             46.1 ± 12.4
  Underlying kidney disease                
   Chronic glomerulonephritis              14 (58.3)
   Diabetes                                3 (12.5)
   Hypertensive nephrosclerosis            1 (4.2)
   Cystic disease                          4 (16.7)
   Others                                  2 (8.3)
  Living donor transplantation             16 (66.7)
  Cross-match positive KT                  1 (4.2)
  ABO incompatible KT                      2 (8.3)
  Pre-transplant PRA positive              3 (12.5)
  The median time from KT to biopsy, mon   14 (0--94)
  HLA mismatch number                      
   Total                                   3 (0--6)
   DR                                      1 (0--2)
  Induction treatment                      
   Basiliximab                             24 (100.0)
  CNI                                      
   Tacrolimus                              21 (87.5)
   Cyclosporine                            3 (12.5)

Values are shown as mean ± standard deviation, median (range), or frequency (percentage). The percentage PRA and antibody specificity were determined by Luminex assays and PRA \> 10% was considered as positive.

KTRs = kidney transplant recipients, KT = kidney transplantation, PRA = panel reactive antibody, HLA = human leukocyte antigen, DR = antigen D related, CNI = calcineurin inhibitor.

Clinical and immunologic characteristics of stable KTRs and KTRs who underwent indication biopsy based on MI sum scores
-----------------------------------------------------------------------------------------------------------------------

There were no significant differences in age, sex, KT types, and the number of HLA mismatches between the MI ≥ 1 group (n = 13) and the normal control group (n = 82; [Table 2](#T2){ref-type="table"}). No significant differences in the clinical and immunologic characteristics were observed between the 2 groups based on their MI sum scores ([Table 2](#T2){ref-type="table"}). Two KTRs (20.0%) in the MI = 0 group and 6 KTRs (46.2%) in the MI ≥ 1 group developed de novo DSA. There was a trend for higher median MFI of DSA in the MI ≥ 1 group compared with MI = 0 group, although the difference did not reach statistical significance. The mean of g + ptc was 3.08 ± 1.55 in the MI ≥ 1 group. In the MI ≥ 1 group (n = 13), 5 (38.5%) were acute AMR, 1 (7.7%) was chronic active AMR, 5 (38.5%) had TCMR, 1 (7.7%) had acute and chronic interstitial nephritis, and 1 (7.7%) had a non-specific diagnosis. In the MI = 0 group (n = 11), 1 (9.1%) had TCMR, 6 (54.5%) had a non-specific diagnosis, and 2 (18.2%) had chronic CNI toxicity, 1 (9.1%) had BK virus nephropathy, and 1 (9.1%) had chronic transplant glomerulopathy. Among 6 KTRs with AMR, 2 were C4d positive AMR and 4 were C4d negative AMR. There was a significant difference in the histological diagnosis of renal allograft between 2 groups (*P* = 0.004).

###### Baseline characteristics of KTRs with stable renal function and KTRs who underwent indication biopsy based on the sum scores of MI
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  Variables                       Control (n = 82)   MI = 0 (n = 11)        MI ≥ 1 (n = 13)          *P* value^\*^   *P* value^†^
  ------------------------------- ------------------ ---------------------- ------------------------ --------------- --------------
  Male sex                        49 (59.8)          9 (81.8)               7 (53.8)                 0.766           0.211
  Mean age, yr                    45.8 ± 10.8        44.1 ± 15.3            47.9 ± 9.6               0.486           0.471
  Underlying kidney disease                                                                          0.002           0.176
   Chronic glomerulonephritis     50 (61.0)          5 (45.5)               9 (69.2)                                 
   Diabetes                       20 (24.4)          3 (27.3)               0 (0.0)                                  
   Hypertensive nephrosclerosis   5 (6.1)            1 (9.1)                0 (0.0)                                  
   Cystic disease                 0 (0.0)            1 (9.1)                3 (23.1)                                 
   Others                         7 (8.5)            1 (9.1)                1 (7.7)                                  
  Living donor transplantation    64 (78.0)          8 (72.7)               8 (61.5)                 0.293           0.679
  Cross-match positive KT         0 (0.0)            0 (0.0)                1 (7.7)                  0.137           1.000
  ABO incompatible KT             0 (0.0)            1 (9.1)                1 (9.1)                  0.137           1.000
  HLA mismatch number                                                                                                
   Total                          3 (0--6)           3 (2--6)               3 (0--6)                 0.298           0.691
   DR                             1 (0--2)           1 (0--2)               1 (0--2)                 0.981           0.608
  CNI                                                                                                0.048           1.000
   Tacrolimus                     81 (98.8)          10 (90.9)              11 (84.6)                                
   Cyclosporine                   1 (1.2)            1 (9.1)                2 (15.4)                                 
  g + ptc-score                   \-                 \-                     3.08 ± 1.55              \-              \-
  De novo DSA, %                  \-                 2 (20.0)               6 (46.2)                 \-              0.184
  De novo DSA intensity, MFI      \-                 1,203 (1,013--1,393)   11,512 (5,007--19,882)   \-              0.071
  Diagnosis (Banff 2013)                                                                             \-              0.004
   Normal                         \-                 6 (54.5)               1 (7.7)                                  
   TCMR                           \-                 1 (9.1)                5 (38.5)                                 
   Acute AMR                      \-                 0 (0.0)                5 (38.5)                                 
   Chronic active AMR             \-                 0 (0.0)                1 (7.7)                                  
   Others                         \-                 4 (36.4)               1 (7.7)                                  
  C4d positive AMR                \-                 \-                     2 (15.4)                 \-              \-
  C-reactive protein, mg/dL       \-                 0.09 (0.01--4.01)      0.09 (0.04--3.91)        \-              0.861

Values are shown as mean ± standard deviation (Student\'s t-test), median (range; Mann-Whitney U test), or frequency (percentage). Others include chronic CNI toxicity (n = 2), acute and chronic interstitial nephritis (n = 1), BK virus nephropathy (n = 1), and chronic transplant glomerulopathy (n = 1).

KTRs = kidney transplant recipients, MI = microcirculation inflammation, KT = kidney transplantation, HLA = human leukocyte antigen, DR = antigen D related, CNI = calcineurin inhibitor, g = glomerulitis, ptc = peritubular capillaritis, DSA = donor-specific antibody, MFI = mean fluorescence intensity, TCMR = T cell mediated rejection, AMR = antibody-mediated rejection.

^\*^Significance of the difference between normal control and MI ≥ 1. **^†^**Significance of the difference between MI = 0 and MI ≥ 1.

Comparisons of T lymphocyte subsets and HLA-DR-positive monocyte between the stable KTRs and 2 groups of KTRs who underwent indication biopsy according to the sum scores of MI
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The frequencies of CD4^+^HLA-DR^+^/CD4^+^ T cells and CD8^+^HLA-DR^+^/CD8^+^ T cells at the time of biopsy were significantly increased in KTRs with an MI sum score ≥ 1 (n = 13), when compared with KTRs with an MI sum score = 0 (n = 11) (26.2% \[range 5.0%--42.7%\] vs. 10.3% \[range 4.1%--24.1%\] and 51.9% \[range 18.6%--71.8%\] vs. 27.9% \[range 6.2%--64.7%\]; *P* = 0.018 and *P* = 0.037, respectively; [Fig. 1](#F1){ref-type="fig"}). No significant differences were observed in the percentage of CD4^+^CD25^+^/CD4^+^ T cells, CD8^+^CD25^+^/CD8^+^ T cells, and HLA-DR^+^ monocytes, and HLA-DR^+^ monocytes MFI between the 2 groups based on the sum score of MI (MI ≥ 1 vs. MI = 0; 6.5% \[range 0.1%--12.4%\] vs. 4.3% \[range 0.8%--25.6%\]; 0.2% \[range 0.0%--2.3%\] vs. 0.3% \[range 0.0%--2.0%\]; 99.0% \[range 84.0%--100.0%\] vs.100.0% \[range 87.0%--100.0%\]; and 276.0 \[range 49.0--596.0\] vs. 278.0 \[range 65.0--490.0\], respectively; [Fig. 1](#F1){ref-type="fig"}). The frequencies of CD4^+^HLA-DR^+^/CD4^+^ T cells and CD8^+^HLA-DR^+^/CD8^+^ T cells were also significantly increased in KTRs with an MI sum score ≥ 1 (n = 13) compared to KTRs in the normal control group (n = 82) (26.2% \[range 5.0%--42.7%\] vs. 13.2% \[range 2.6%--39.3%\] and 51.9% \[range 18.6%--71.8%\] vs. 37.8% \[range 7.3%--73.5%\]; *P* = 0.015 and *P* = 0.038, respectively; [Fig. 1](#F1){ref-type="fig"}). However, the flow cytometric results showed no difference between the MI = 0 group (n = 11) and the normal control group (n = 82).

![Comparisons of T lymphocyte subsets and HLA-DR-positive monocyte between the stable KTRs and 2 groups of KTRs according to the sum scores of MI. The frequencies of CD4^+^HLA-DR^+^/CD4^+^ T cells and CD8^+^HLA-DR^+^/CD8^+^ T cells at the time of biopsy were significantly increased in KTRs with MI sum score ≥ 1 (n = 13) in KTRs with an MI sum score = 0 (n = 11; *P* = 0.018 and *P* = 0.037, respectively) as well as KTRs in the normal control group (*P* = 0.015 and *P* = 0.038, respectively).\
HLA-DR = human leukocyte antigen-antigen D related, KTRs = kidney transplant recipients; MI = microcirculation inflammation, DR = antigen D related, MFI = mean fluorescence intensity.\
^\*^*P* \< 0.05.](jkms-32-908-g001){#F1}

Comparisons of T lymphocyte subsets and HLA-DR-positive monocytes by the sum scores of i + t, ci + ct, and cv + ah
------------------------------------------------------------------------------------------------------------------

When the enrolled KTRs who underwent indication biopsy were categorized according to the sum scores of i + t, ci + ct, and cv + ah, there were no significant differences in circulating T lymphocyte subsets and HLA-DR-positive monocytes between the 2 groups ([Fig. 2](#F2){ref-type="fig"}). The frequencies of CD4^+^HLA-DR^+^/CD4^+^ T cells and CD8^+^HLA-DR^+^/CD8^+^ T cells between the 2 groups based on the sum scores of i + t, ci + ct, and cv + ah are as follows: 1) i + t ≥ 1 vs. i + t = 0; 15.8% (range 5.0%--39.2%) vs. 10.6% (range 4.1%--42.7%) and 49.0% (range 18.6%--71.8%) vs. 32.1% (range 6.2%--69.9%), respectively; 2) ci + ct ≥ 1 vs. ci + ct = 0; 12.3% (range 4.1%--36.1%) vs. 22.0% (range 5.3%--42.7%) and 41.4% (range 6.2%--71.8%) vs. 41.3% (range 36.4%--69.9%), respectively; and 3) cv + ah ≥ 1 vs. cv + ah = 0; 18.5% (range 5.0%--36.1%) vs. 13.7% (range 4.1%--42.7%) and 53.1% (range 18.6%--71.8%) vs. 36.2% (range 6.2%--69.9%), respectively ([Fig. 2](#F2){ref-type="fig"}).

![Comparisons of T lymphocyte subsets and HLA-DR-positive monocytes between 2 groups according to the sum scores of i + t, ci + ct, and cv + ah. When 2 groups were categorized according to the sum scores of i + t, ci + ct, and cv + ah, serum T lymphocyte subsets and HLA-DR positive monocytes showed no significant differences between 2 groups.\
HLA-DR = human leukocyte antigen-antigen D related, i = inflammation, t = tubulitis, ci = interstitial fibrosis, ct = tubular atrophy, cv = fibrointimal thickening, ah = arteriolar hyaline thickening, DR = antigen D related, MFI = mean fluorescence intensity.](jkms-32-908-g002){#F2}

Correlation between MI sum scores, the MFI of de novo DSA, and T lymphocyte subsets/HLA-DR positive monocytes
-------------------------------------------------------------------------------------------------------------

When we analyzed the correlations between the MI sum scores and T lymphocyte subsets/HLA-DR-positive monocytes, CD4^+^HLA-DR^+^/CD4^+^ T cells were only positively correlated with MI sum scores (*P* = 0.016; [Table 3](#T3){ref-type="table"}). The MFI of de novo DSA showed a trend for an increased frequency of CD4^+^HLA-DR^+^/CD4^+^ T cells, although this association did not reach statistical significance (*P* = 0.058; [Table 3](#T3){ref-type="table"}).

###### Correlation between T lymphocyte subsets/HLA-DR positive monocytes and MI and the MFI of de novo DSA
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  Cell subsets                     MI       MFI of de novo DSA            
  -------------------------------- -------- -------------------- -------- -------
  CD4^+^CD25^+^/CD4^+^ T cells     0.062    0.774                0.071    0.867
  CD8^+^CD25^+^/CD8^+^ T cells     0.130    0.545                −0.229   0.586
  CD4^+^HLA-DR^+^/CD4^+^ T cells   0.486    0.016                0.690    0.058
  CD8^+^HLA-DR^+^/CD8^+^ T cells   0.344    0.099                0.595    0.120
  HLA-DR^+^ monocytes, %           −0.360   0.084                0.246    0.558
  HLA-DR MFI on monocytes          −0.018   0.934                0.168    0.691

HLA-DR = human leukocyte antigen-antigen D related, MI = microcirculation inflammation, MFI = mean fluorescence intensity, DSA = donor-specific antibody.

Identifying the intraluminal cell types in glomeruli and peritubular capillaries by immunohistochemistry
--------------------------------------------------------------------------------------------------------

We have performed immunohistochemical cell counting in 1 TCMR with MI = 0, 4 TCMR with MI ≥ 2, and 4 AMR with MI ≥ 2. Immune-stain for CD68^+^ have revealed that AMR with MI ≥ 2 have more CD68^+^ macrophages in glomerular and peritubular capillary compared to TCMR with MI ≥ 2 (21.1 ± 5.2 vs. 6.0 ± 2.2; *P* = 0.029; [Fig. 3](#F3){ref-type="fig"}). In contrast, the average number of CD3^+^ T cells in glomerular and peritubular capillary was higher in TCMR with MI ≥ 2 compared to AMR with MI ≥ 2 (22.0 ± 6.5 vs. 0.6 ± 0.5; *P* = 0.029; [Fig. 3](#F3){ref-type="fig"}). In addition, CD3^+^ T cells and CD68^+^ macrophages in TCMR with MI = 0 were not detected in glomeruli and peritubular capillaries. Representative figures for CD3^+^ T cells and CD68^+^ macrophages in glomeruli and peritubular capillaries according to the histological diagnosis were presented in the [Fig. 3](#F3){ref-type="fig"}.

![Intraluminal cell types in glomeruli and peritubular capillaries by immunohistochemistry. (**A-D**) Representative figures for CD3^+^ T cells (**A**) and CD68^+^ macrophages (**B**) in AMR with MI ≥ 2 and CD3^+^ T cells (**C**) and CD68^+^ macrophages (**D**) in TCMR with MI ≥ 2 (immunoperoxidase, original magnification × 200). (**E**) Comparisons of mean numbers of positive cells for CD3 and CD68 in glomerular and peritubular capillaries in biopsies with AMR with MI ≥ 2 (n = 4) versus TCMR with MI ≥ 2 (n = 4) versus TCMR with MI = 0 (n = 1). The average numbers of CD3^+^ T cells and CD68^+^ macrophages were significantly increased in TCMR with MI ≥ 2 biopsies (*P* = 0.029) and AMR with MI ≥ 2 biopsies (*P* = 0.029), respectively.\
AMR = antibody-mediated rejection, MI = microcirculation inflammation, TCMR = T cell mediated rejection.](jkms-32-908-g003){#F3}

Analysis using the ROC curve for predicting AMR
-----------------------------------------------

Analysis using the ROC curve showed that AMR could be predicted with a sensitivity of 80.0% and a specificity of 94.7% using a cutoff value of 29.6% frequency of CD4^+^HLA-DR^+^/CD4^+^ T cells. The areas under the curve of circulating CD4^+^HLA-DR^+^/CD4^+^ T cells for predicting AMR were 0.874 ([Fig. 4](#F4){ref-type="fig"}).

![Analysis using the ROC curve. AMR could be predicted with a sensitivity of 80.0% and a specificity of 94.7% using a cutoff value of 29.6% frequency of CD4^+^HLA-DR^+^/CD4^+^ T cells. The areas under the curve of circulating CD4^+^HLA-DR^+^/CD4^+^ T cells for predicting AMR was 0.874.\
ROC = receiver operating characteristic, AMR = antibody-mediated rejection.](jkms-32-908-g004){#F4}

DISCUSSION
==========

The present study investigated the association between immune activation in the peripheral blood at the time of biopsy and histopathological findings of renal allografts in KTRs who underwent indication biopsy. We found that KTRs with MI had an increased frequency of activated T lymphocytes expressing HLA-DR in the circulation compared with KTRs without MI as well as KTRs with stable renal function. However, the flow cytometric analysis of circulating T lymphocyte subsets and monocytes was not found to be associated with the sum of scores of i + t, ci + ct, and cv + ah.

AMR is a major obstacle for maintaining long-term graft survival in KTRs. Although the DSA titer is most commonly used for diagnosing AMR, it has limitations as a non-invasive monitoring tool for AMR. Not all KTRs with DSA develop AMR and certain DSA do not activate the complement cascade that drives the formation of the membrane attack complex, which damages the renal allograft endothelium. Therefore, more reliable, non-invasive immunologic monitoring tools for predicting AMR are needed to improve renal allograft survival.

The main target of AMR is the microcirculation endothelium of the donor\'s peritubular and glomerular capillaries ([@B10]). Local immune responses, such as antibody ligation, initiation of the complement system activation, recruitment of immune cells, endothelial damage, loss of vascular integrity, and increased coagulation occur in the microcirculation endothelium ([@B10]). Previous studies have attempted to assess and diagnose AMR by using a microarray-based test of tissue from renal allografts ([@B11][@B12][@B13][@B14][@B15][@B16]). Gene expression microarray studies have reported consistent results that gene transcriptions related to endothelial activation and injury, T lymphocyte, natural killer cells, macrophages, and cytokines were increased in AMR biopsy specimens ([@B11][@B12][@B13][@B14][@B15][@B16]). However, microarray-based assessment of AMR is difficult to apply in clinical practice and is an invasive procedure. Therefore, in the present study, we sought to establish a significant link between the systemic immune response and local histopathologic injury of tissue from renal allografts.

A number of studies have attempted to discover the convincing biomarkers in KTRs with acute rejection. Studies regarding messenger RNA profiles using real-time polymerase chain reaction have reported that expression of Granzyme B and perforin in the peripheral blood, which are the cytotoxic T-cell markers, was up-regulated during acute rejection in KTRs ([@B17][@B18][@B19][@B20][@B21][@B22]). However, a recent meta-analysis regarding the significance of Granzyme B and perforin as noninvasive diagnostic biomarkers for acute rejection have demonstrated that neither Granzyme B nor perforin alone could be a reliable noninvasive diagnostic biomarker for acute rejection in KTRs ([@B23]). Several studies have reported that pretransplant donor-specific interferon-γ-producing cells detected by enzyme-linked immunosorbent spot assay ([@B24][@B25][@B26]), sCD30 protein before and 15-day after transplant evaluated by enzyme-linked immunosorbent assay ([@B27]), and pretransplant antiendothelial cell (anti-Tie-2) antibodies detected by flow cytometry ([@B28]) were associated with the development of acute rejection in KTRs. However, these peripheral blood biomarkers have not been used in clinical practice.

In our study, the frequencies of CD4^+^HLA-DR^+^/CD4^+^ T cells and CD8^+^HLA-DR^+^/CD8^+^ T cells in the peripheral blood were significantly increased in KTRs with MI but not in KTRs with i + t ≥ 1, ci + ct ≥ 1, and cv + ah ≥ 1. The sum scores of MI and i + t indicate AMR-related lesions and TCMR-related lesions, respectively. The sum scores ci + ct and cv + ah indicate atrophy-scarring-related lesions, suggesting chronic histopathological changes. The results of the flow cytometric analysis of peripheral blood T lymphocyte subsets and monocytes suggest that MI is the most acute and active histopathological finding and influenced by the systemic immune response. Significant difference of the flow cytometric results between KTRs with MI and KTRs with stable renal function also confirms this result. In these 2 subsets, only CD4^+^ T lymphocytes expressing HLA-DR correlated strongly with the sum scores of MI. The ROC analysis demonstrated that circulating CD4^+^HLA-DR^+^/CD4^+^ T cells could be considered to be a good predictor for AMR.

According to Banff 2013 classification, as long as there are serologic evidence of DSAs and C4d staining in peritubular capillaries, AMR can be diagnosed with an MI sum score ≥ 1 (g \> 0 and/or ptc \> 0) ([@B2]). In the study by Sis et al. ([@B29]) including 329 indication biopsies from 251 renal allograft recipients, any degree of MI (g + ptc \> 0) in late kidney transplant biopsies strongly indicates presence of DSA and predicts progression to graft failure. Loupy et al. ([@B30]) have reported that KTRs with C4d-negative subclinical AMR at 3 months (defined as g + ptc \> 0) had more ptc and ci and ct and a lower glomerular filtration rate at 1 year compared to those without subclinical lesions at 3 months. Like these, previous studies have demonstrated the clinical significance of any degree of MI. And so, we used an MI sum score ≥ 1 as a cutoff value. Moreover, in our study, the frequencies of CD4^+^HLA-DR^+^/CD4^+^ T cells at the time of biopsy were also significantly increased in KTRs with an MI sum score ≥ 2 (n = 9), when compared with KTRs with an MI sum score = 0 (n = 11) (30.5% vs. 10.3%; *P* = 0.038).

Among KTRs with MI ≥ 1, 5 patients (38.5%) were diagnosed with acute AMR and 5 patients (38.5%) were diagnosed with TCMR. This result reflects that MI is not a specific histopathological feature for AMR and increased activities of T lymphocyte do not always confirm the presence of AMR. Therefore, the monitoring of circulating CD4^+^HLA-DR^+^/CD4^+^ T cells in conjunction with DSA could maximize the assessment and diagnosis of AMR in KTRs.

T lymphocytes, especially CD4^+^ T cells, are activated by the recognition of donor major histocompatibility complex antigens displayed by the endothelium, and subsequently contribute to the production of alloantibodies. Activation of the complement cascade by DSA leads to the formation of C3b, C3a, C5b, and C5a. These major effector molecules result in the formation of the membrane attack complex and activation of endothelial cells and T lymphocytes, which further amplifies the immune response ([@B31][@B32][@B33]). This immune process can eventually cause histopathological changes and injury in renal allografts. Among circulating immune cells, T lymphocytes are closely related to renal parenchymal damage, considering the crucial role of this cell-type which plays in the initiation and amplification of the overall immune response. Hayde et al. ([@B11]) have reported increased serum immune activities involving the activation, regulation, and differentiation of T lymphocytes only in DSA-positive/AMR-positive KTRs, but not in DSA-positive/AMR-negative KTRs. These findings are in agreement with those from our study, in that increased immune activity in the peripheral blood is a crucial trigger that alters histopathological findings in the renal allograft in KTRs. Taken together, these results suggest that systemic immune activation might precede the active intragraft immune response.

Previous studies dealing with the intragraft immune reaction in KTRs have demonstrated the infiltration of T cells, monocytes, and HLA-DR expressing cells in renal allografts with rejection ([@B4][@B5][@B6]). In rejected renal allografts, the extent of infiltrates of T lymphocytes in the glomerulus and vascular endothelium and monocytes expressing HLA-DR increased with the severity of rejection ([@B5][@B6]). Expression of HLA-DR antigens in the graft was considered to be an indicator of immune inflammation and a starting point for the rejection response. Previous studies assessing the immune status of peripheral blood reported that a low expression of HLA-DR antigens in the peripheral monocytes was associated with increased infectious complications in solid organ transplant recipients, which implied that decreased HLA-DR expression is an indicator of generalized monocyte dysfunction ([@B34][@B35]). These results correspond to those from other immunohistological studies, in that a significant connection exists between the expression of HLA-DR and an activated immune status. However, the clinical relevance of HLA-DR expressing immune cells in the peripheral blood, which might precede the local immune changes in KTRs with allograft dysfunction, is not well known.

We performed immunohistochemical cell counting for CD3^+^ and CD68^+^ to identify how these immune cells in the biopsies correlate with HLA-DR^+^ T cells in the peripheral blood. Among biopsy specimens with higher MI sum scores which mean increased circulating T lymphocytes expressing HLA-DR, the average numbers of CD3^+^ T cells and CD68^+^ macrophages were significantly increased in TCMR and AMR, respectively. Our findings of immunohistochemical stain showed consistent with the results of previous studies. Previous studies conducted by Sis et al. ([@B29]) and Hidalgo et al. ([@B14]) have also demonstrated that CD3^+^ T cells in glomeruli or peritubular capillaries were predominant in TCMR biopsies and CD68^+^ macrophages in AMR biopsies. This result can be explained by interactions between CD4^+^ T cells and macrophages. Interferon-γ produced by CD4^+^ T cells, along with tumor necrosis factor from antigen-presenting cells, can induce classically activated macrophages, which secrete interleukin-1 (IL-1), IL-6, IL-12, IL-18, and IL-23 ([@B36]). Activated macrophages during acute rejection promote inflammation and induce tissue damage by secreting a large number of cytokines, nitric oxide, and superoxide ([@B37]). Although multiple cell types infiltrated renal allografts, macrophage infiltration was associated with renal allograft dysfunction ([@B6][@B38]) and renal tubular stress, as indicated by HLA-DR expression, while T cell infiltration was not ([@B6]). It is possible to speculate that the relationship between activated T cells and macrophage give rise to microvascular injury of renal allografts in KTRs with AMR.

Though the findings from our study are clinically significant, this study is not without limitations. First, the sample size is small. Further large-scale, multicenter studies are needed to confirm the results of our study. Second, the alteration of systemic immune activity and histopathologic findings after treatment of acute rejection were not defined. Further studies are needed to demonstrate the changes of the immune activity in peripheral blood and histopathologic findings by performing serial blood sampling and protocol biopsy. Third, the best cutoff point of CD4^+^HLA-DR^+^/CD4^+^ T cells have not been validated in a separate independent cohort. Further validation of this immunologic marker is needed in large-scale cohort. Fourth, we did not perform protocol biopsies for KTRs with stable renal function, which would have yielded more useful results. Therefore, we cannot completely exclude the possibility that MI and chronic scarring changes can be present in KTRs with stable renal function. However, the strength of this study is that we demonstrated the association between the histopathological findings of allograft and systemic immune activation at the time of indication biopsy and identified a useful, noninvasive immunologic monitoring tool for the prediction of AMR in KTRs. To the best of our knowledge, this is the first report to reveal the significant association between MI and an increased frequency of circulating CD4^+^ T lymphocytes expressing HLA-DR.

In conclusion, HLA-DR expressing CD4^+^ T lymphocytes in the peripheral blood are an index of systemic immune activation in KTRs and are associated with histopathological injury of renal allografts. Early diagnosis and prompt treatment are essential for rescuing grafts with suspected AMR. Monitoring and detection of circulating CD4^+^HLA-DR^+^/CD4^+^ T cells with DSA in KTRs could reduce the burden of graft damage induced by AMR. This study provides the basis for future investigations dealing with activated T lymphocytes as a monitoring tool and potential therapeutic target for AMR in KTRs.
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